Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$5.08 -5.8%	$4.78	$3.42 ▼ $7.05	$286.77M	1.84	1.91 million shs	1.59 million shs
APLT Applied Therapeutics	$0.48 +1.5%	$0.41	$0.30 ▼ $10.62	$67.83M	1.97	2.65 million shs	736,253 shs
DRUG Bright Minds Biosciences	$41.82 -1.7%	$29.86	$0.94 ▼ $79.02	$294.41M	-6.07	49,887 shs	51,008 shs
GALT Galectin Therapeutics	$3.57 -5.1%	$2.70	$0.73 ▼ $4.41	$225.95M	0.82	414,798 shs	185,876 shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	-2.53%	+28.03%	+20.04%	+5.07%	-21.54%
APLT Applied Therapeutics	+4.54%	+8.96%	+11.66%	-21.71%	-92.03%
DRUG Bright Minds Biosciences	+4.93%	+22.24%	+74.63%	+28.91%	+4,111.88%
GALT Galectin Therapeutics	+2.45%	-2.08%	+34.29%	+193.75%	+80.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACB Aurora Cannabis	0.6714 of 5 stars	0.0	3.0	0.0	2.2	0.8	0.6
APLT Applied Therapeutics	4.4641 of 5 stars	3.3	3.0	4.7	3.3	1.7	1.3
DRUG Bright Minds Biosciences	2.5654 of 5 stars	3.6	2.0	0.0	3.0	2.5	0.0
GALT Galectin Therapeutics	2.0599 of 5 stars	3.5	0.0	0.0	2.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	3.00	Buy	N/A	N/A
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,173.22% Upside
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	99.07% Upside
GALT Galectin Therapeutics	3.00	Buy	$6.00	68.07% Upside

Current Analyst Ratings Breakdown

Latest APLT, DRUG, GALT, and ACB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
8/8/2025	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
6/17/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/21/2025	DRUG Bright Minds Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$246.72M	1.16	$0.56 per share	9.05	$7.54 per share	0.67
APLT Applied Therapeutics	$460K	147.46	N/A	N/A	$0.49 per share	0.98
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$0.92 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.68) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	$1.63M	-$0.19	N/A	11.55	N/A	-5.66%	-1.49%	-1.06%	N/A
APLT Applied Therapeutics	-$105.62M	-$0.43	N/A	N/A	N/A	N/A	-312.21%	-124.26%	N/A
DRUG Bright Minds Biosciences	-$2.06M	-$0.36	N/A	N/A	N/A	N/A	-14.56%	-14.29%	N/A
GALT Galectin Therapeutics	-$47.05M	-$0.72	N/A	N/A	N/A	N/A	N/A	-216.05%	N/A

Latest APLT, DRUG, GALT, and ACB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	DRUG Bright Minds Biosciences	-$0.59	-$0.53	+$0.06	-$0.53	N/A	N/A
8/14/2025	Q2 2025	GALT Galectin Therapeutics	-$0.16	-$0.12	+$0.04	-$0.12	N/A	N/A
8/13/2025	Q2 2025	APLT Applied Therapeutics	-$0.17	-$0.15	+$0.02	-$0.15	$0.42 million	N/A
8/6/2025	Q1 2026	ACB Aurora Cannabis	$0.18	-$0.19	-$0.37	-$0.20	$96.83 million	$71.98 million
6/18/2025	Q4 2025	ACB Aurora Cannabis	$0.11	$0.07	-$0.04	-$0.24	$88.85 million	$63.34 million
5/15/2025	Q2 2025	DRUG Bright Minds Biosciences	-$0.39	-$0.29	+$0.10	-$0.29	N/A	N/A
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.06	2.97	1.51
APLT Applied Therapeutics	N/A	3.00	3.00
DRUG Bright Minds Biosciences	N/A	126.01	126.01
GALT Galectin Therapeutics	N/A	0.08	0.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
APLT Applied Therapeutics	98.31%
DRUG Bright Minds Biosciences	40.52%
GALT Galectin Therapeutics	11.68%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
APLT Applied Therapeutics	1.60%
DRUG Bright Minds Biosciences	42.66%
GALT Galectin Therapeutics	50.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,130	56.45 million	56.45 million	Optionable
APLT Applied Therapeutics	30	141.58 million	139.31 million	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
GALT Galectin Therapeutics	9	63.29 million	31.58 million	Optionable

APLT, DRUG, GALT, and ACB Headlines

Recent News About These Companies

Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are individual investors with 54% stake, while 21% is held by insiders

1 hour ago | finance.yahoo.com

Galectin Therapeutics Reports Reduced Losses in Q2 2025

August 15 at 6:52 AM | msn.com

Galectin Beats Q2 Loss Estimates

August 14 at 10:49 AM | aol.comA

Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Tuesday

August 10, 2025 | americanbankingnews.com

Galectin Therapeutics (NASDAQ:GALT) Share Price Crosses Above 200 Day Moving Average - Here's Why

August 9, 2025 | marketbeat.com

Galectin Therapeutics (GALT) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

July 30, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Takes Position in Galectin Therapeutics Inc. (NASDAQ:GALT)

July 30, 2025 | marketbeat.com

Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200 Day Moving Average - Here's Why

July 22, 2025 | marketbeat.com

Galectin Therapeutics Announces New $10 Million Credit Line from ...

July 11, 2025 | morningstar.comM

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026

July 9, 2025 | taiwannews.com.twT

Galectin Therapeutics Inc. (GALT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galectin Therapeutics Inc. Common Stock (GALT)

June 20, 2025 | nasdaq.com

Galectin Therapeutics Inc.

June 20, 2025 | wsj.com

Galectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension Treatment

June 11, 2025 | nasdaq.com

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

June 10, 2025 | finance.yahoo.com

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update

May 17, 2025 | seekingalpha.com

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

May 12, 2025 | globenewswire.com

Why Galectin Therapeutics Inc.’s (GALT) Stock Is Up 14.71%

May 7, 2025 | aaii.comA

Why Galectin Therapeutics Inc.’s (GALT) Stock Is Down 5.07%

April 22, 2025 | aaii.comA

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress

April 15, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

APLT, DRUG, GALT, and ACB Company Descriptions

Aurora Cannabis NASDAQ:ACB

$5.08 -0.31 (-5.75%)

Closing price 04:00 PM Eastern

Extended Trading

$5.18 +0.11 (+2.07%)

As of 04:27 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Applied Therapeutics NASDAQ:APLT

$0.48 +0.01 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$0.48 0.00 (-0.86%)

As of 04:26 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Bright Minds Biosciences NASDAQ:DRUG

$41.82 -0.72 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$41.62 -0.20 (-0.47%)

As of 04:31 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Galectin Therapeutics NASDAQ:GALT

$3.57 -0.19 (-5.05%)

Closing price 04:00 PM Eastern

Extended Trading

$3.64 +0.08 (+2.10%)

As of 04:10 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time